Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved

Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved

Source: 
Fierce Biotech
snippet: 

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease (AD) patients.

That’s the top-line verdict, anyway, after another setback in the field, this time from the phase 2 Tauriel trial of Roche and partner AC Immune’s anti-tau antibody, semorinemab, in early (prodromal to mild) AD.